HCW Biologics Inc.

HCW Biologics Inc.

HCWB · Nasdaq

HCW Biologics Inc. (HCWB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for HCW Biologics Inc. in 2026. The next earnings report is expected on November 12, 2026.

Earnings calendar

Next earnings date

12 Nov 2026

In 83 days

EPS estimate

-1.08

Revenue estimate

—

Past earnings

14 Aug 2026
EPS actual
-11.58 (-484.8%)
estimate -1.98
Revenue actual
135.6K
estimate 7.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
11 May 2026
EPS actual
—
estimate -0.44
Revenue actual
—
estimate 7.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
31 Mar 2026
EPS actual
-1.02 (-21.4%)
estimate -0.84
Revenue actual
5.4K (-99.9%)
estimate 7.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
14 Nov 2025
EPS actual
-4.13 (-361.4%)
estimate 1.58
Revenue actual
85.3K (-98.8%)
estimate 7.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

HCW Biologics Inc. missed consensus estimates in its latest earnings report, with EPS of -$11.58 versus an estimate of -$1.98 and revenue of $135.57 thousand versus an estimate of $7.01 million, falling 98.1% short of expectations. In the previous quarter both EPS and revenue also missed expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Hing C. Wong
Employees
36
IPO date
20 Jul 2021
ISIN
US40423R2040
Website
hcwbiologics.com

Frequently asked questions

When does HCW Biologics Inc. (HCWB) next report earnings?

HCW Biologics Inc. (HCWB) is scheduled to report earnings on November 12, 2026.

What was HCW Biologics Inc.'s most recent earnings date?

HCW Biologics Inc. (HCWB) last reported earnings on August 14, 2026.

Where is HCW Biologics Inc. stock listed?

HCW Biologics Inc. (HCWB) is listed on Nasdaq.